Methods of diagnosis and treatment of endoplasmic reticulum (er) stress-related conditions
AssigneeMassachusetts Institute of Technology
InventorsPaul Chang, Miri Jwa, Sejal Kamlesh Vyas
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for treating endoplasmic reticulum (ER) stress-related conditions (e.g., cancer, protein folding/misfolding disease, diabetes mellitus) and for identifying compounds for treating ER stress-related conditions in a subject (e.g., a human). The invention also provides methods for diagnosing an ER stress-related condition in a subject and kits for the treatment of same.
Claims18
1-32. (canceled)
A method of treating a subject with an ER stress-related condition, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition that decreases PARP-16 expression or activity.
A method of treating a subject with an ER stress-related condition, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition that increases PARP-16 expression or activity.
A method of diagnosing an endoplasmic reticulum (ER) stress-related condition in a subject, the method comprising analyzing the level of poly(ADP-ribose) polymerase 16 (PARP-16) expression or activity in a sample isolated from the subject, wherein an increased level of PARP-16 expression or activity in the sample relative to the level in a control sample indicates that the subject has the ER stress-related condition.
A method of identifying a candidate compound useful for treating a subject having an ER stress-related condition, the method comprising:
- (a) contacting a PARP-16 protein, or fragment thereof, with a compound;
- and
- (b) measuring the activity of the PARP-16, wherein a decrease in PARP-16 activity in the presence of the compound identifies the compound as a candidate compound for treating an ER stress-related condition in a subject.
A method of identifying a candidate compound useful for treating a subject having an ER stress-related condition, the method comprising:
- (a) contacting a PARP-16 protein, or fragment thereof, with a compound;
- and
- (b) measuring the activity of the PARP-16, wherein an increase in PARP-16 activity in the presence of the compound identifies the compound as a candidate compound for treating an ER stress-related condition in a subject.
A kit for treating a subject with an ER stress-related condition, the kit comprising:
- (a) a pharmaceutical composition that modulates PARP-16 expression or activity;
- and
- (b) instructions for administering the pharmaceutical composition to the subject.
Dependencies are inferred from the claim text.